Vote Scores
Filings read through

How funds voted at Inhibikase Therapeutics, Inc.

Ticker
IKT
SEC company number
1750149
Filers reporting
134, year to 30 June 2026
Latest meeting on file
Meetings on file
4

In the year to 30 June 2026, 134 filers on Form N-PX reported votes at Inhibikase Therapeutics, Inc.. The votes fall in one meeting. The figures count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting. Filers gave 437 marks to the ballot items, each with or against management. 63.4% of the marks are with management.

On say-on-pay, 95 of the 124 reporting filers that marked the item voted against management. This is 76.6% of the filers. Of the reported shares, 33.4% went against management. The median of the 3,799 companies on this site with a say-on-pay item is 6.6% of filers and 2.9% of reported shares.

At the meeting of 26 Jun 2026, 5 fund families have a say-on-pay position with management and 27 have a position against management.

By filers reporting in the year to 30 June 2026, Inhibikase Therapeutics, Inc. was number 3,224 of 11,972 companies with a page and votes in that year. The number of filers reporting at Inhibikase Therapeutics, Inc. rose by 1388.9% from the year to 30 June 2025 to the year to 30 June 2026. At the companies on this site with filers in both years, the total of filers reporting rose by 6.0%. In all seasons on file, category SECTION 14A SAY-ON-PAY VOTES is 47.1% of the vote records at Inhibikase Therapeutics, Inc.. At all companies on this site, it is 12.3%.

ForAgainstAbstain, withhold or otherAmber tick: the part cast against management

If the reporting person has not received confirmation of the actual number of votes cast prior to filing a report on Form N-PX, the numbers reported may reflect the number of shares instructed to be cast. A reporting person is not required to amend a previously filed Form N-PX report if the reporting person subsequently receives confirmation of the actual number of votes cast.

The words of the SEC. Source: Form N-PX and its instructions, Special Instructions D.5 and D.8, copied on .

The words of this site: the filer writes each filing. The SEC does not say that it checked the votes. A lender does not vote shares that are on loan. A later filing (Form N-PX/A) can replace an earlier filing, and the site uses the latest.

The figures on this page count the filers that report on Form N-PX and the shares they reported. They do not count all votes cast at the meeting.

The page gives records. It gives no investment advice and no advice on how to vote.

Season on this page: year to 30 June 2026. Filings read through . How the figures are made

Since the last update

The site has recorded no change in the tracked figures of this page.

Tracked: the meetings on file and the date of the latest meeting. All recorded changes

The ballot of 26 Jun 2026

134 filers reported votes at this meeting in the year to 30 June 2026. The items are in ballot order: the company's items first, then proposals from security holders. Each bar shows how the reporting filers split. It is not the result of the meeting. The meeting page has the split by reported shares and a CSV file.

  1. Item 1: Director elections

    2 nominees. 46.1% of the reported votes are for. 37 filers withheld from or voted against at least one nominee.

    178 vote records from 48 filers. 16 of the 48 filers that marked the item voted against management.

    • Positions of 26 fund families
    • For 9
    • Abstain or withhold 10
    • Split or no vote 7
    • Against management 10
  2. Item 2: Advisory vote on executive pay (say-on-pay)

    213 vote records from 131 filers. 95 of the 124 filers that marked the item voted against management. 7 filers gave no management mark.

    • Positions of 32 fund families
    • For 5
    • Against 27
    • Against management 27
  3. Item 3: Frequency of the say-on-pay vote

    One year: 116 filers. For: 5 filers. Not applicable: 2 filers. Against: 1 filer. 1-year: 1 filer. Abstain: 1 filer.

    199 vote records from 130 filers. 0 of the 124 filers that marked the item voted against management. 6 filers gave no management mark.

    • Positions of 32 fund families
    • For 1
    • Split or no vote 31
  4. Item 4: Audit-related items (auditor ratification)

    85 vote records from 48 filers. 0 of the 48 filers that marked the item voted against management.

    • Positions of 26 fund families
    • For 26
  5. Item 5: COMPENSATION: management items

    The company's items in this category are shown together, because filers word and number them differently.

    90 vote records from 49 filers. 45 of the 49 filers that marked the item voted against management.

    • Positions of 26 fund families
    • Against 26
    • Against management 25
  6. Item 6: CORPORATE GOVERNANCE: management items

    The company's items in this category are shown together, because filers word and number them differently.

    77 vote records from 44 filers. 4 of the 44 filers that marked the item voted against management.

    • Positions of 25 fund families
    • For 21
    • Against 4
    • Against management 3

Positions of the fund families at the meeting of 26 Jun 2026

A position is not the vote of each fund. The position of a family is the way most of the shares reported by its filers were voted. Funds of one family can vote in different ways.

KeyForAgainstAbstain or withholdSplit or no voteAgainst management

Fund families at Inhibikase Therapeutics, Inc., meeting of 26 Jun 2026Families in name order. "Abstain" includes withhold. "Split" includes no vote. "No report" means that no filer of the family listed the item.
Fund familySay-on-pay
AllianceBernsteinAgainst, against management
American CenturyAgainst, against management
BlackRock and iSharesAgainst, against management
BNY MellonFor
Brighthouse FundsFor
Charles SchwabAgainst, against management
DWSAgainst, against management
EquitableAgainst, against management
FidelityAgainst, against management
Global XAgainst, against management
Goldman SachsFor
Guggenheim and RydexAgainst, against management
InvescoAgainst, against management
J.P. MorganFor
John Hancock and ManulifeAgainst, against management
Lincoln FinancialAgainst, against management
Morgan Stanley, Eaton Vance and CalvertAgainst, against management
NationwideAgainst, against management
Neuberger BermanAgainst, against management
Northern Trust and FlexSharesAgainst, against management
Nuveen and TIAAAgainst, against management
Pacific Life fundsAgainst, against management
PGIM and PrudentialAgainst, against management
PrincipalAgainst, against management
ProShares and ProFundsAgainst, against management
Russell InvestmentsAgainst, against management
SEIAgainst, against management
State Street and SPDRAgainst, against management
T. Rowe PriceAgainst, against management
VanguardAgainst, against management
Victory CapitalAgainst, against management
VoyaFor

Every meeting on file

Meetings of Inhibikase Therapeutics, Inc., from Form N-PX filings, newest firstA meeting with 20 or more reporting filers has its own page. Dates up to three days apart count as one meeting.
MeetingSeasonFilers reportingItemsFilers against management on say-on-pay
year to 30 June 2026134676.6%
year to 30 June 2025840.0%
year to 30 June 2025310.0%
year to 30 June 2025310.0%

Say-on-pay, season by season

Say-on-pay at Inhibikase Therapeutics, Inc.: filers reporting on Form N-PXThe share of filers, and of the shares they reported, that voted against management.
SeasonFilers reportingFilers against managementReported shares against management
year to 30 June 202613476.6%33.4%
year to 30 June 202590.0%0.0%
Inhibikase Therapeutics, Inc. and the median of companies on this site, year to 30 June 2026
Say-on-payThis companyMedian of companies on this site
Filers against management76.6%6.6%
Reported shares against management33.4%2.9%

The median covers 3,799 companies. Each has a say-on-pay item that 20 or more filers reported. The two figures are not a grade. The median is a reference only.

Vote records at Inhibikase Therapeutics, Inc. by category, every seasonThe category is the one each filer chose.
CategoryVote recordsShare
DIRECTOR ELECTIONS19922.3%
SECTION 14A SAY-ON-PAY VOTES42147.1%
AUDIT-RELATED9610.7%
COMPENSATION10111.3%
CORPORATE GOVERNANCE778.6%

The record at the SEC

Each link loaded on .

Embed this card on your site

Copy this code into your page. The card shows the figures above with their source. A line under the card links to this page.

How embedding works. It is free. Keep the link in the card and the link line under it.

Cite this page

Vote Scores. How funds voted at Inhibikase Therapeutics, Inc.. https://votescores.com/company/inhibikase-therapeutics-inc/. Source: SEC EDGAR, Form N-PX and N-PX/A filings read through .

Questions

How many meetings of Inhibikase Therapeutics, Inc. are on file?
4 meetings are on file, from 5 Aug 2024 to 26 Jun 2026. 1 meeting has 20 or more reporting filers and has its own page.
Did filers report proposals from security holders at Inhibikase Therapeutics, Inc.?
Not enough filers reported a proposal from security holders for the site to show one in the year to 30 June 2026. The ballot shows the items that filers did report.
Is this the meeting result?
No. The figures count the filers that report on Form N-PX and the shares they reported. Other holders are not in the count. Inhibikase Therapeutics, Inc. reports the result of a vote on Form 8-K.
How does the site group meetings and names?
Filers type company names and meeting dates themselves. The site groups spellings of one company name. It treats meeting dates up to three days apart as one meeting. The data runs through 13 Nov 2026.

Provenance: SEC EDGAR, Form N-PX and N-PX/A filings that list Inhibikase Therapeutics, Inc., grouped by company. The name is the most common spelling among filers. The ticker and the SEC company number come from the SEC company tickers file, matched on the exact name. The filers wrote the filings. Filings read through .